معرفی
Dr. Ross Campbell is a Clinical Senior Lecturer at the University of Glasgow and an Honorary Consultant Cardiologist at both the Queen Elizabeth University Hospital and Golden Jubilee National Hospital in Glasgow. He specializes in heart failure and cardiac imaging, particularly focusing on novel diuretic therapies and the application of artificial intelligence in clinical workflows. His research includes leading multicenter trials such as EMPRESS-MI (assessing empagliflozin's effects post-myocardial infarction) and trials investigating subcutaneous furosemide delivery systems for heart failure management. He completed his BSc in Physiology and MBChB at the University of Glasgow, followed by a PhD under Professors John McMurray and Mark Petrie. His academic roles include senior clinical lecturer positions and career recognition such as the 2019 Chief Science Officer NRS Fellowship. Key research themes center on diuretic optimization, cardiac MRI biomarkers, and improving outcomes through technology integration.
- Education: BSc Physiology (2004), MBChB (2006) - University of Glasgow
- Affiliations: BHF Glasgow Cardiovascular Research Facility
His research interests emphasize translational medicine, with a focus on:
- Novel drug-device combinations (e.g., subcutaneous furosemide patches)
- AI-driven diagnostic tools for heart failure
- Biomarker development for congestion and remodelling assessment
- Clinical trial design for HFpEF/HFrEF populations
Recent work highlights include the SUGAR-DM-HF study evaluating empagliflozin’s effects on left ventricular volumes and the BIOPEF project exploring biomarkers in HFpEF patients. He leads the Glasgow Biomarker Centre of Clinical Excellence in Heart Failure and collaborates on grants from Roche, AstraZeneca, and Boehringer Ingelheim.
Grants & Awards:
- OASIS Project (Stroke Association, 2024-2027)
- Glasgow Biomarker Centre (Roche, 2022-2027)
- EMPRESS-MI Trial (Boehringer Ingelheim, 2021-2025)
His academic contributions span 58+ peer-reviewed publications and active involvement in clinical trials addressing unmet needs in heart failure management.